Global Hypertensive Heart Disease Market Research and Forecast, 2018-2023
Hypertensive heart diseases refer to heart failure, CAD (coronary artery disease), and thickening of heart muscles, due to high blood pressure. Other diseases caused by high blood pressure includes a stroke, ischemic heart disease, peripheral artery disease, aneurysms, and other kidney diseases. The rising prevalence of hypertensive heart diseases & awareness program by government organizations, and high global healthcare expenditure is boosting the growth of hypertensive heart disease market. Additionally, rising medical tourism in emerging economies such as China, Thailand and India, are some factors driving market growth. Global hypertensive heart disease market is segmented into diagnosis and therapeutics. Based on the diagnosis, the market is divided into electrocardiogram, echocardiogram, coronary angiography, others. On the basis of therapeutics, the market is bifurcated into drugs and surgery. The high cost of the diagnostics and therapeutics technologies, side effects of the hypertensive drugs, and strict government policies are restraining the global hypertensive heart disease market. The introduction of pipeline products for the treatment of hypertensive disorders is one of the major opportunities anticipated to propel the market growth in the near future.
Global hypertensive heart disease market has been analyzed as per geographical standpoint, including North America, Europe, Asia-Pacific, and Rest of the World. High prevalence of hypertensive heart diseases and the rising expenditure on healthcare in the US has further boosted the growth of the market in North America. The rapidly emerging economies in Asia-Pacific are projected to exhibit the fastest growth rate in the global hypertensive heart disease market during the forecast period. The growth in the Asia-Pacific hypertensive heart disease market is backed by the growing awareness regarding the diagnosis and treatment options for heart diseases within the countries. Along with it, the regular efforts made by government organizations with expenditure on R&D and funding programs is fueling the growth of the market in the region.
The key players operating in the global hypertensive disease market include Abbott Laboratories, Bayer AG, AstraZeneca PLC, Merck KGaA, Novartis AG, Pfizer Inc., and Sanofi SA, among others. Product launch, merger & acquisition, and partnerships are some of the key strategies adopted by the market players and sustain and capture the major market share in the hypertensive heart disease market.
RESEARCH METHODOLOGY
The market study of hypertensive heart disease market is incorporated by extensive primary and secondary research conducted by a research team at OMR. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.
SECONDARY SOURCES INCLUDE
MARKET SEGMENTATION
1. Global Hypertensive Heart Disease Market Research and Analysis by Diagnosis
2. Global Hypertensive Heart Disease Market Research and Analysis by Therapeutics
The report covers
Global hypertensive heart disease market has been analyzed as per geographical standpoint, including North America, Europe, Asia-Pacific, and Rest of the World. High prevalence of hypertensive heart diseases and the rising expenditure on healthcare in the US has further boosted the growth of the market in North America. The rapidly emerging economies in Asia-Pacific are projected to exhibit the fastest growth rate in the global hypertensive heart disease market during the forecast period. The growth in the Asia-Pacific hypertensive heart disease market is backed by the growing awareness regarding the diagnosis and treatment options for heart diseases within the countries. Along with it, the regular efforts made by government organizations with expenditure on R&D and funding programs is fueling the growth of the market in the region.
The key players operating in the global hypertensive disease market include Abbott Laboratories, Bayer AG, AstraZeneca PLC, Merck KGaA, Novartis AG, Pfizer Inc., and Sanofi SA, among others. Product launch, merger & acquisition, and partnerships are some of the key strategies adopted by the market players and sustain and capture the major market share in the hypertensive heart disease market.
RESEARCH METHODOLOGY
The market study of hypertensive heart disease market is incorporated by extensive primary and secondary research conducted by a research team at OMR. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.
SECONDARY SOURCES INCLUDE
- Financial reports of companies involved in the market
- Whitepapers, research-papers and news blogs
- Company websites and their product catalog.
- Supplier Websites such as Alibaba, Amazon for pricing analysis.
MARKET SEGMENTATION
1. Global Hypertensive Heart Disease Market Research and Analysis by Diagnosis
2. Global Hypertensive Heart Disease Market Research and Analysis by Therapeutics
The report covers
- Comprehensive research methodology of global hypertensive heart disease market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global hypertensive heart disease market.
- Insights about market determinants which are stimulating the global hypertensive heart disease market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
CHAPTER 1. REPORT SUMMARY
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. Definition
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendation
2.2.3. Conclusion
2.3. Rules & Regulations
CHAPTER 3. MARKET DETERMINANT
3.1. Motivators
3.1.1. High Prevalence of Hypertensive Heart Diseases
3.1.2. Patient Assistance Programs by Government Organizations
3.1.3. Rising Global Expenditure on Healthcare Sector
3.1.4. Rising Medical Tourism in Emerging Economies
3.2. Restraint
3.2.1. High Cost of Diagnostics and Treatment Therapies
3.2.2. Side Effects of Hypertensive Drugs
3.2.3. Strict Government Regulations and Policies
3.3. Opportunity
3.3.1. Strong Pipeline Products for Treatment of Hypertensive Heart Diseases
3.3.2. Growing Awareness in Emerging Economies
3.3.3. Rising R&D for Hypertensive Heart Diseases
CHAPTER 4. MARKET SEGMENTATION
4.1. Global Hypertensive Heart Disease Market by Diagnosis
4.1.1. Electrocardiogram
4.1.2. Echocardiogram
4.1.3. Coronary Angiography
4.1.4. Others (Chest X-Ray)
4.2. Global Hypertensive Heart Disease Market by Therapeutics
4.2.1. Drugs
4.2.1.1. Thiazide Diuretics
4.2.1.2. Beta Blockers
4.2.1.3. Angiotensin Converting Enzyme (ACE) Inhibitors
4.2.1.4. Angiotensin II Receptor Blockers (Arb)
4.2.1.5. Calcium Channel Blockers
4.2.1.6. Others (Renin Inhibitors)
4.2.2. Surgery
4.2.2.1. Coronary Artery Bypass Surgery
4.2.2.2. Transmyocardial Laser Revascularization
4.2.2.3. Heart Transplant
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. Key Strategy Analysis
5.2. Key Company Analysis
CHAPTER 6. REGIONAL ANALYSIS
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. RoE
6.3. Asia-Pacific
6.3.1. India
6.3.2. China
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World (RoW)
CHAPTER 7. COMPANY PROFILES
7.1. Abbott Laboratories
7.2. AstraZeneca PLC
7.3. Actelion Pharmaceuticals Ltd.
7.4. Boehringer Ingelheim International GmbH
7.5. Bayer AG
7.6. Eiger BioPharmaceuticals, Inc.,
7.7. Daiichi Sankyo Co., Ltd.
7.8. Gilead Sciences, Inc.
7.9. GlaxoSmithKline PLC
7.10. F. Hoffmann-La Roche Ltd.
7.11. Johnson & Johnson Services, Inc.
7.12. Lupin Pharmaceuticals, Inc.
7.13. Merck KGaA
7.14. Novartis AG
7.15. Pfizer Inc.
7.16. Sanofi SA
7.17. Sun Pharmaceutical Industries Ltd.
7.18. Takeda Pharmaceutical Co. Ltd.
7.19. United Therapeutics Corp.
7.20. Northern Therapeutics Inc.
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. Definition
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendation
2.2.3. Conclusion
2.3. Rules & Regulations
CHAPTER 3. MARKET DETERMINANT
3.1. Motivators
3.1.1. High Prevalence of Hypertensive Heart Diseases
3.1.2. Patient Assistance Programs by Government Organizations
3.1.3. Rising Global Expenditure on Healthcare Sector
3.1.4. Rising Medical Tourism in Emerging Economies
3.2. Restraint
3.2.1. High Cost of Diagnostics and Treatment Therapies
3.2.2. Side Effects of Hypertensive Drugs
3.2.3. Strict Government Regulations and Policies
3.3. Opportunity
3.3.1. Strong Pipeline Products for Treatment of Hypertensive Heart Diseases
3.3.2. Growing Awareness in Emerging Economies
3.3.3. Rising R&D for Hypertensive Heart Diseases
CHAPTER 4. MARKET SEGMENTATION
4.1. Global Hypertensive Heart Disease Market by Diagnosis
4.1.1. Electrocardiogram
4.1.2. Echocardiogram
4.1.3. Coronary Angiography
4.1.4. Others (Chest X-Ray)
4.2. Global Hypertensive Heart Disease Market by Therapeutics
4.2.1. Drugs
4.2.1.1. Thiazide Diuretics
4.2.1.2. Beta Blockers
4.2.1.3. Angiotensin Converting Enzyme (ACE) Inhibitors
4.2.1.4. Angiotensin II Receptor Blockers (Arb)
4.2.1.5. Calcium Channel Blockers
4.2.1.6. Others (Renin Inhibitors)
4.2.2. Surgery
4.2.2.1. Coronary Artery Bypass Surgery
4.2.2.2. Transmyocardial Laser Revascularization
4.2.2.3. Heart Transplant
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. Key Strategy Analysis
5.2. Key Company Analysis
CHAPTER 6. REGIONAL ANALYSIS
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. RoE
6.3. Asia-Pacific
6.3.1. India
6.3.2. China
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World (RoW)
CHAPTER 7. COMPANY PROFILES
7.1. Abbott Laboratories
7.2. AstraZeneca PLC
7.3. Actelion Pharmaceuticals Ltd.
7.4. Boehringer Ingelheim International GmbH
7.5. Bayer AG
7.6. Eiger BioPharmaceuticals, Inc.,
7.7. Daiichi Sankyo Co., Ltd.
7.8. Gilead Sciences, Inc.
7.9. GlaxoSmithKline PLC
7.10. F. Hoffmann-La Roche Ltd.
7.11. Johnson & Johnson Services, Inc.
7.12. Lupin Pharmaceuticals, Inc.
7.13. Merck KGaA
7.14. Novartis AG
7.15. Pfizer Inc.
7.16. Sanofi SA
7.17. Sun Pharmaceutical Industries Ltd.
7.18. Takeda Pharmaceutical Co. Ltd.
7.19. United Therapeutics Corp.
7.20. Northern Therapeutics Inc.
LIST OF TABLES
TABLE # 1 GLOBAL HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLIONS)
TABLE # 2 GLOBAL ELECTROCARDIOGRAM MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
TABLE # 3 GLOBAL ECHOCARDIOGRAM MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
TABLE # 4 GLOBAL CORONARY ANGIOGRAPHY MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
TABLE # 5 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
TABLE # 6 GLOBAL HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2017-2023 ($ MILLIONS)
TABLE # 7 GLOBAL DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
TABLE # 8 GLOBAL SURGERY MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
TABLE # 9 GLOBAL HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLIONS)
TABLE # 10 NORTH AMERICA HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 11 NORTH AMERICA HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 12 NORTH AMERICA HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2017-2023 ($ MILLION)
TABLE # 13 EUROPE HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 14 EUROPE HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 15 EUROPE HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2017-2023 ($ MILLION)
TABLE # 16 ASIA-PACIFIC HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 17 ASIA-PACIFIC HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 18 ASIA-PACIFIC HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2017-2023 ($ MILLION)
TABLE # 19 ROW HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 20 ROW HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2017-2023 ($ MILLION)
TABLE # 1 GLOBAL HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLIONS)
TABLE # 2 GLOBAL ELECTROCARDIOGRAM MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
TABLE # 3 GLOBAL ECHOCARDIOGRAM MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
TABLE # 4 GLOBAL CORONARY ANGIOGRAPHY MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
TABLE # 5 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
TABLE # 6 GLOBAL HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2017-2023 ($ MILLIONS)
TABLE # 7 GLOBAL DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
TABLE # 8 GLOBAL SURGERY MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
TABLE # 9 GLOBAL HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLIONS)
TABLE # 10 NORTH AMERICA HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 11 NORTH AMERICA HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 12 NORTH AMERICA HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2017-2023 ($ MILLION)
TABLE # 13 EUROPE HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 14 EUROPE HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 15 EUROPE HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2017-2023 ($ MILLION)
TABLE # 16 ASIA-PACIFIC HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 17 ASIA-PACIFIC HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 18 ASIA-PACIFIC HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2017-2023 ($ MILLION)
TABLE # 19 ROW HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 20 ROW HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2017-2023 ($ MILLION)
LIST OF FIGURES
FIGURE # 1 GLOBAL HYPERTENSIVE HEART DISEASE MARKET SHARE BY DIAGNOSIS, 2017 VS 2023 (%)
FIGURE # 2 GLOBAL HYPERTENSIVE HEART DISEASE MARKET SHARE BY THERAPEUTICS, 2017 VS 2023 (%)
FIGURE # 3 GLOBAL HYPERTENSIVE HEART DISEASE MARKET SHARE BY GEOGRAPHY, 2017 VS 2023 (%)
FIGURE # 4 US HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 5 CANADA HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 6 UK HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 7 FRANCE HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 8 GERMANY HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 9 ITALY HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 10 SPAIN HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 11 ROE HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 12 INDIA HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 13 CHINA HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 14 JAPAN HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 15 REST OF ASIA-PACIFIC HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 16 ROW HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 1 GLOBAL HYPERTENSIVE HEART DISEASE MARKET SHARE BY DIAGNOSIS, 2017 VS 2023 (%)
FIGURE # 2 GLOBAL HYPERTENSIVE HEART DISEASE MARKET SHARE BY THERAPEUTICS, 2017 VS 2023 (%)
FIGURE # 3 GLOBAL HYPERTENSIVE HEART DISEASE MARKET SHARE BY GEOGRAPHY, 2017 VS 2023 (%)
FIGURE # 4 US HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 5 CANADA HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 6 UK HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 7 FRANCE HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 8 GERMANY HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 9 ITALY HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 10 SPAIN HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 11 ROE HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 12 INDIA HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 13 CHINA HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 14 JAPAN HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 15 REST OF ASIA-PACIFIC HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 16 ROW HYPERTENSIVE HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
